The VA Is Testing a GLP-1 for Alcohol Use Disorder
The Department of Veterans Affairs began recruiting on July 28. The study tests semaglutide as a treatment for alcohol use disorder. More than 600 veterans will take part across 18 medical centers. For clinics running mental health and weight loss programs together, this study sits on the seam between them.
Running two service lines under one roof only works if the overhead on both stays controlled. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The trial | The VA is testing weekly semaglutide against placebo in more than 600 veterans with alcohol use disorder |
| The scale | 18 VA medical centers, ages 18 to 80, 24 weeks of treatment plus safety monitoring |
| Why the VA is looking | Earlier research found lower rates of alcohol and substance use disorders among GLP-1 users |
| The clinic overlap | Many practices now run ketamine and GLP-1 programs side by side, often for the same patients |
| The compliance line | Nothing here approves a GLP-1 for addiction. Marketing one that way invites enforcement |
Interested in peptide therapy? Find vetted peptide therapy clinics near you.
What the VA Is Testing
Participants are aged 18 to 80 with moderate or severe alcohol use disorder. They receive weekly injections of semaglutide or placebo. Treatment runs 24 weeks. Safety monitoring follows.
Researchers will track drinking behavior, health outcomes and quality of life. The design matters as much as the drug. This trial is randomized and placebo controlled. That separates it from the observational work that prompted it.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and ketamine clinics closest to you as well as other psychedelic therapies in your area.
Why Anyone Suspected This Would Work
The rationale came from patterns in existing patient records. Research published earlier this year looked at people taking GLP-1 medications. They showed lower rates of alcohol and substance use disorders than similar patients on other diabetes drugs.
Among patients who already had a substance use disorder, GLP-1 use tracked with fewer emergency visits. Hospitalizations fell too.
Those findings are correlations, not proof. People prescribed GLP-1 drugs differ from people who are not. Some of those differences resist statistical adjustment. Closing that gap is what a randomized trial is for.
The Crossover Your Practice May Already Run
This lands differently for interventional psychiatry than for endocrinology. Many ketamine practices added GLP-1 or peptide services over the past two years. Most did it as a cash pay line that steadies revenue between infusion series.
Those clinics now treat two populations that overlap heavily. Depression, anxiety and problem drinking travel together. Metabolic disease travels with all three.
Picture one patient. She receives ketamine for treatment resistant depression. She also receives semaglutide for weight loss. Your practice may be treating one interconnected problem under two unrelated plans.
If this trial reads out positive, that arrangement stops looking like two service lines. It starts looking like integrated care.
The Line You Cannot Cross Yet
Now the caution. Semaglutide is not approved for alcohol use disorder. A trial that began recruiting last week proves nothing about efficacy.
Any clinic describing its GLP-1 program as a treatment for drinking or cravings is making an unapproved claim. That is exactly the conduct drawing federal attention right now.
We covered the mechanics in our anatomy of an FDA GLP-1 warning letter. The wider pattern appears in the agency’s crackdown on compounded GLP-1 marketing. Enforcement in this category targets website language, not clinical judgment.
What to Do With This Now
Three moves are reasonable today.
Screen properly. Alcohol use screening belongs in intake for both programs. The comorbidity is real whatever this trial finds.
Document outcomes across both lines. Track what happens to patients enrolled in both. That record has value if the evidence turns, and value to a payer or partner regardless.
Keep the marketing clean. Watch the trial and prepare the operations. Say nothing publicly that the FDA has not approved. Clinics weighing the combination can start with our guide to adding peptide services to a ketamine practice.
